tafenoquine has been researched along with Plasmodium vivax Malaria in 60 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (3.33) | 18.2507 |
2000's | 11 (18.33) | 29.6817 |
2010's | 29 (48.33) | 24.3611 |
2020's | 18 (30.00) | 2.80 |
Authors | Studies |
---|---|
Breton, JJ; Chau, NH; Duparc, S; Ernest, TB; Goyal, N; Green, JA; Hien, TT; Hoa, NT; Jones, SW; Martin, A; Mohamed, K; Rolfe, K; Rousell, VM; Sharma, H; Tan, LK; Taylor, M; Vélez, ID | 1 |
Herrera, S; Hsiang, MS; Llanos-Cuentas, A; Manrrique, P; Rosas-Aguirre, A | 1 |
Nekkab, N; Watson, JA; White, M | 1 |
Gautam, CS; Sharma, J; Singh, H; Singh, J | 1 |
Choi, JY; Kim, C; Kim, JD; Kim, JH; Lee, J; Suh, J; Yeom, JS | 1 |
Baird, JK; Berni, A; Budiman, W; Cedar, E; Chand, K; Crenna-Darusallam, C; Duparc, S; Ekawati, LL; Elyazar, I; Fernando, D; Fletcher, K; Goyal, N; Green, JA; Instiaty, I; Jones, S; Kleim, JP; Lardo, S; Martin, A; Noviyanti, R; Prasetya, CB; Rolfe, K; Santy, YW; Satyagraha, AW; Sharma, H; Soebandrio, A; Subekti, D; Sutanto, I; Tan, LK; Taylor, M | 1 |
Commons, RJ; Thriemer, K | 1 |
Markus, MB | 1 |
Janković, SM; Kostić, M; Milosavljević, MN; Ranković, G; Stefanović, S | 1 |
Awab, GR; Contantia, F; Day, NP; Devine, A; Gilchrist, K; Green, JA; Hailu, A; Koh, GC; Lubell, Y; Ngo, VT; Nguyen, TN; Pasaribu, AP; Pham, HT; Price, RN; Taylor, WR; Teferi, T; Thriemer, K; Tran, TH | 1 |
Derbyshire, ER; Lu, KY | 1 |
Chalon, S; Duparc, S; Miller, S; Richardson, N; Toovey, S | 1 |
Devine, A; Dittrich, S; Howes, RE; Ley, B; Moore, KA; Price, DJ; Price, RN; Simpson, JA | 1 |
Breton, JJ; Duparc, S; Espino, FEJ; Green, JA; Hien, TT; Koh, GCKW; Krudsood, S; Lacerda, MVG; Llanos-Cuentas, A; Lon, C; Mohammed, R; Namaik-Larp, CS; Pereira, DB; Saunders, DL; St Jean, PL; Velez, ID; Villegas, MF; Yilma, D | 1 |
Sayers, DR; Webber, BJ | 1 |
Fernando, D; Rajapakse, S; Rodrigo, C | 2 |
Chu, CS; Hwang, J | 1 |
Contreras-Mancilla, J; Delgado-Ratto, C; Fernandez-Miñope, C; Ferrucci, HR; Gamboa, D; Llanos-Cuentas, A; Van Geertruyden, JP | 1 |
Ahmad, SS; Rahi, M; Sharma, A | 1 |
Lacerda, M; Lana, R; Monteiro, W; Mueller, I; Nekkab, N; Obadia, T; Siqueira, A; Villela, D; White, M | 1 |
Dow, G; Smith, B | 1 |
Buathong, N; Euswas, A; Fukuda, MM; Green, JA; Ittiverakul, M; Krudsood, S; Miller, RS; Mohamed, K; Noedl, H; Ohrt, C; Sriwichai, S; Warrasak, S | 1 |
Bancone, G; Chu, CS; Jittamala, P; Taylor, WRJ; Watson, J; White, NJ | 1 |
Bancone, G; Bansil, P; Chu, CS; Domingo, GJ; Gornsawun, G; Nosten, F; Pal, S; Porn, P | 1 |
Hwang, J; Tan, KR | 1 |
Euswas, A; Fukuda, MM; Ittiverakul, M; Krudsood, S; Miller, RS; Ohrt, C; Warrasak, S | 1 |
Baird, JK | 1 |
Berman, J; Brown, T; Dow, G; Toovey, S | 1 |
White, NJ | 1 |
Abdissa, A; Abebe, C; Angus, B; Batista Pereira, D; Beck, HP; Brand, F; Breton, JJ; Brito, MAM; Buathong, N; Casapía, M; Chuquiyauri, R; Clover, DD; Costa, MRF; Diro, E; Duparc, S; Espino, FEJ; Fletcher, K; Getie, S; Green, JA; Hardaker, E; Jones, SW; Kellam, LM; Kleim, JP; Koh, GCKW; Krudsood, S; Lacerda, MVG; Llanos-Cuentas, A; Lon, C; Mia, RZ; Mohamed, K; Mohammed, R; Monteiro, WM; Noedl, H; Rousell, VM; Saunders, DL; Tada, MS; Ugwuegbulam, CO; Val, F; Wubie, KM; Yilma, D; Zeynudin, A | 1 |
Angus, B; Aruachan, S; Bancone, G; Breton, JJ; Brito, MAM; Casapía, M; Chu, CS; Chuquiyauri, R; Clover, DD; Costa, MRF; Craig, G; Duparc, S; Green, JA; Hardaker, E; Hien, TT; Jones, SW; Kendall, L; Koh, GCKW; Lacerda, MVG; Llanos-Cuentas, A; Mohamed, K; Monteiro, WM; Namaik-Larp, C; Nguyen, CH; Nosten, FH; Papwijitsil, R; Rousell, VM; Val, F; Vélez, ID; Villegas, MF; Wilches, VM | 1 |
McCarthy, S; Quinn, JC | 1 |
Taylor, AR; Watson, JA | 1 |
Duparc, S; Green, JA; Koh, GCKW | 1 |
Bifani, P; Chuenchob, V; Dembele, L; Diagana, TT; Flannery, EL; Gupta, DK; Ishino, T; Kangwanrangsan, N; Kappe, SH; Kocken, CH; Mikolajczak, S; Roma, G; Sattabongkot, J; Vaughan, AM; Voorberg-van der Wel, A; Yip, A | 1 |
Chen, V; Daily, JP | 1 |
Arthur, P; Carter, N; Chuenchom, N; Duparc, S; Green, JA; Gupta, SK; Kellam, L; Kleim, JP; Kochar, SK; Krudsood, S; Lacerda, MV; Llanos-Cuentas, A; Möhrle, JJ; Rueangweerayut, R; Ugwuegbulam, C | 1 |
Nosten, F; Price, RN | 1 |
Dow, GS; McCarthy, WF; Reid, M; Shanks, GD; Smith, B; Tang, D | 1 |
Burrows, JN; Campo, B; Vandal, O; Wesche, DL | 1 |
Fernando, SD; Rajapakse, S; Rodrigo, C | 1 |
Goyal, N; Green, JA; Tenero, D | 1 |
Beck, HP; Carter, N; Duparc, S; Green, JA; Koh, G; Krudsood, S; Lacerda, MV; Llanos-Cuentas, A; Osorio, L; Rubio, JP; Rueangweerayut, R; Wampfler, R | 1 |
Beaumont, C; Carter, N; Duparc, S; Green, JA; Koh, GC; Krudsood, S; Llanos-Cuentas, A; Rubio, JP; Rueangweerayut, R; St Jean, PL; Taylor, M; Xue, Z | 1 |
Abay, SM; Ebstie, YA; Ejigu, DA; Tadesse, WT | 1 |
Bouhired, S; Duparc, S; Goyal, N; Green, JA; Hussaini, A; Jones, SW; Koh, GC; Kostov, I; Mohamed, K; Taylor, M; Wolstenholm, A | 1 |
Edstein, MD; Elmes, NJ; Kitchener, SJ; Kocisko, DA; Nasveld, PE | 1 |
Peters, W; Robinson, BL; Stewart, LB | 1 |
Coleman, RE; Eikarat, N; Kittayapong, P; Ponsa, N; Sattabongkot, J | 1 |
Brewer, TG; Cherdchu, C; Eamsila, C; Edstein, MD; Jarasrumgsichol, P; Khaewsathien, P; Rieckmann, KH; Sangkharomya, S; Sasiprapha, T; Supakalin, P; Tang, DB; Walsh, DS | 1 |
Brewer, TG; Heppner, DG; Krudsood, S; Looareesuwan, S; Phumratanaprapin, W; Silachamroon, U; Siriyanonda, D; Tang, DB; Walsh, DS; Wilairatana, P | 1 |
Kitchener, S; Nasveld, P | 1 |
Edstein, MD; Gatton, ML; Kitchener, SJ; Kocisko, DA; Nasveld, PE; Rieckmann, KH | 1 |
Edstein, MD; Kitchener, S; Nasveld, P | 1 |
Crockett, M; Kain, KC | 1 |
Cooper, RD; Kyle, DE; Nuzum, EO; Obaldia, N; Rieckmann, KH; Rossan, RN; Shanks, GD | 1 |
Braitman, DJ; Brewer, TG; Brueckner, RP; Chokejindachai, W; Heppner, DG; Horton, J; Kyle, DE; Looareesuwan, S; Milhous, WK; Schuster, BG; Tang, DB; Viriyavejakul, P; Walsh, DS; Wilairatana, P | 1 |
Eamsila, C; Edstein, MD; Kitchener, S; Nasveld, PE; Rieckmann, KH; Sasiprapha, T; Walsh, DS | 1 |
Brewer, TG; Charles, BG; Eamsila, C; Edstein, MD; Kocisko, DA; Walsh, DS | 1 |
14 review(s) available for tafenoquine and Plasmodium vivax Malaria
Article | Year |
---|---|
Tafenoquine for the treatment of
Topics: Aminoquinolines; Antimalarials; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine; Recurrence | 2022 |
Tafenoquine for
Topics: Aminoquinolines; Antimalarials; Female; Humans; Malaria, Vivax; Plasmodium vivax; Pregnancy; Primaquine; Recurrence | 2021 |
Neurological and psychiatric safety of tafenoquine in Plasmodium vivax relapse prevention: a review.
Topics: Aminoquinolines; Antimalarials; Humans; Malaria, Vivax; Nervous System Diseases; Plasmodium vivax; Secondary Prevention | 2020 |
Tafenoquine for preventing relapse in people with Plasmodium vivax malaria.
Topics: Adult; Aminoquinolines; Antimalarials; Chloroquine; Drug Administration Schedule; Glucosephosphate Dehydrogenase Deficiency; Humans; Malaria, Vivax; Parasitemia; Placebos; Primaquine; Randomized Controlled Trials as Topic; Recurrence; Secondary Prevention | 2020 |
Tafenoquine: a toxicity overview.
Topics: Adult; Aminoquinolines; Animals; Antimalarials; Dose-Response Relationship, Drug; Glucosephosphate Dehydrogenase Deficiency; Humans; Malaria, Vivax; Mental Disorders | 2021 |
The blood schizonticidal activity of tafenoquine makes an essential contribution to its prophylactic efficacy in nonimmune subjects at the intended dose (200 mg).
Topics: Aminoquinolines; Animals; Antimalarials; Half-Life; Humans; Malaria, Falciparum; Malaria, Vivax; Plasmodium falciparum; Plasmodium vivax; Schizonts | 2017 |
Tafenoquine and primaquine do not exhibit clinical neurologic signs associated with central nervous system lesions in the same manner as earlier 8-aminoquinolines.
Topics: Aminoquinolines; Animals; Antimalarials; Humans; Macaca mulatta; Malaria, Vivax; Primaquine | 2018 |
Tafenoquine: the new kid on the block.
Topics: Aminoquinolines; Antimalarials; Chemoprevention; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Humans; Malaria, Vivax | 2019 |
Killing the hypnozoite--drug discovery approaches to prevent relapse in Plasmodium vivax.
Topics: Aminoquinolines; Antimalarials; Chemical and Drug Induced Liver Injury; Disease Eradication; Drug Discovery; Humans; Liver; Malaria, Vivax; Plasmodium vivax; Recurrence; Sporozoites | 2015 |
Tafenoquine for preventing relapse in people with Plasmodium vivax malaria.
Topics: Adult; Aminoquinolines; Antimalarials; Glucosephosphate Dehydrogenase Deficiency; Humans; Malaria, Vivax; Primaquine; Primary Prevention; Randomized Controlled Trials as Topic; Recurrence | 2015 |
Tafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: the evidence to date.
Topics: Aminoquinolines; Antimalarials; Humans; Malaria, Vivax; Plasmodium vivax | 2016 |
Primaquine in vivax malaria: an update and review on management issues.
Topics: Aminoquinolines; Antimalarials; Artemisinins; Chloroquine; Clinical Trials as Topic; Drug Resistance; Glycogen Storage Disease Type I; Hemolysis; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine | 2011 |
Tafenoquine: a promising new antimalarial agent.
Topics: Aminoquinolines; Animals; Antimalarials; Humans; Malaria, Falciparum; Malaria, Vivax; Recurrence; Treatment Outcome | 2007 |
Malaria prophylaxis/radical cure: recent experiences of the Australian Defence Force.
Topics: Aminoquinolines; Antimalarials; Australia; Controlled Clinical Trials as Topic; Endemic Diseases; Humans; Malaria; Malaria, Falciparum; Malaria, Vivax; Military Personnel; Primaquine | 2001 |
19 trial(s) available for tafenoquine and Plasmodium vivax Malaria
Article | Year |
---|---|
Tafenoquine exposure assessment, safety, and relapse prevention efficacy in children with Plasmodium vivax malaria: open-label, single-arm, non-comparative, multicentre, pharmacokinetic bridging, phase 2 trial.
Topics: Adolescent; Aminoquinolines; Antimalarials; Area Under Curve; Child; Child, Preschool; Chloroquine; Female; Humans; Malaria, Vivax; Male; Recurrence; Secondary Prevention; Tablets | 2022 |
Tafenoquine co-administered with dihydroartemisinin-piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study.
Topics: Antimalarials; Artemisinins; Chloroquine; Drug Therapy, Combination; Humans; Malaria; Malaria, Vivax; Plasmodium vivax; Primaquine; Quinolines | 2023 |
Provider and household costs of
Topics: Absenteeism; Adolescent; Adult; Aged; Aminoquinolines; Antimalarials; Cost of Illness; Cost-Benefit Analysis; Female; Financing, Personal; Global Health; Health Expenditures; Health Services; Humans; Malaria, Vivax; Male; Middle Aged; Models, Economic; Transportation; Young Adult | 2019 |
A randomized, double-blind, active-control trial to evaluate the efficacy and safety of a three day course of tafenoquine monotherapy for the treatment of Plasmodium vivax malaria.
Topics: Adult; Aminoquinolines; Animals; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fever; Humans; Malaria, Vivax; Male; Parasites; Plasmodium vivax; Treatment Outcome; Young Adult | 2017 |
Comparative ophthalmic assessment of patients receiving tafenoquine or chloroquine/primaquine in a randomized clinical trial for Plasmodium vivax malaria radical cure.
Topics: Adult; Aminoquinolines; Antimalarials; Cornea; Dose-Response Relationship, Drug; Double-Blind Method; Eye Infections, Parasitic; Female; Humans; Malaria, Vivax; Male; Middle Aged; Plasmodium vivax; Primaquine; Retina; Retrospective Studies; Slit Lamp Microscopy; Time Factors; Treatment Outcome; Young Adult | 2019 |
Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Cytochrome P-450 CYP2D6; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; Female; Glucosephosphate Dehydrogenase; Hemoglobins; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Logistic Models; Malaria, Vivax; Male; Parasitemia; Plasmodium vivax; Primaquine; Secondary Prevention | 2019 |
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; Female; Glucosephosphate Dehydrogenase; Glucosephosphate Dehydrogenase Deficiency; Hemoglobins; Humans; Kaplan-Meier Estimate; Malaria, Vivax; Male; Parasitemia; Plasmodium vivax; Primaquine; Prospective Studies; Secondary Prevention | 2019 |
Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.
Topics: Adolescent; Adult; Aged; Aminoquinolines; Antimalarials; Brazil; Chloroquine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; India; Malaria, Vivax; Male; Middle Aged; Peru; Primaquine; Secondary Prevention; Thailand; Treatment Outcome; Young Adult | 2014 |
Exposure-Response Analyses for Tafenoquine after Administration to Patients with Plasmodium vivax Malaria.
Topics: Adult; Aminoquinolines; Antimalarials; Double-Blind Method; Female; Humans; Logistic Models; Malaria, Vivax; Male; Plasmodium vivax; Young Adult | 2015 |
Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping.
Topics: Aminoquinolines; Antimalarials; Chloroquine; Dose-Response Relationship, Drug; Double-Blind Method; Genotype; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine; Secondary Prevention | 2016 |
Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial.
Topics: Aminoquinolines; Antimalarials; Chloroquine; Cytochrome P-450 CYP2D6; Female; Humans; Malaria, Vivax; Primaquine; Treatment Outcome | 2016 |
Pharmacokinetic Interactions between Tafenoquine and Dihydroartemisinin-Piperaquine or Artemether-Lumefantrine in Healthy Adult Subjects.
Topics: Adolescent; Adult; Aged; Aminoquinolines; Antimalarials; Artemisinins; Drug Interactions; Drug Therapy, Combination; Ethanolamines; Female; Fluorenes; Half-Life; Healthy Volunteers; Humans; Lumefantrine; Malaria, Vivax; Male; Middle Aged; Plasmodium vivax; Quinolines; Young Adult | 2016 |
The efficacy and tolerability of three different regimens of tafenoquine versus primaquine for post-exposure prophylaxis of Plasmodium vivax malaria in the Southwest Pacific.
Topics: Adult; Aminoquinolines; Animals; Antimalarials; Australia; Dose-Response Relationship, Drug; Female; Humans; Malaria, Vivax; Male; Military Personnel; Plasmodium vivax; Primaquine; Statistics as Topic; Young Adult | 2008 |
Efficacy of monthly tafenoquine for prophylaxis of Plasmodium vivax and multidrug-resistant P. falciparum malaria.
Topics: Administration, Oral; Aminoquinolines; Animals; Antimalarials; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Multiple; Follow-Up Studies; Humans; Malaria, Falciparum; Malaria, Vivax; Military Personnel; Plasmodium falciparum; Thailand; Treatment Outcome | 2004 |
Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Dose-Response Relationship, Drug; Female; Humans; Malaria, Vivax; Male; Methemoglobin; Middle Aged; Primaquine; Risk; Secondary Prevention; Time Factors | 2004 |
Gender differences in gastrointestinal disturbances and plasma concentrations of tafenoquine in healthy volunteers after tafenoquine administration for post-exposure vivax malaria prophylaxis.
Topics: Adult; Aminoquinolines; Antimalarials; Drug Administration Schedule; Drug Monitoring; Female; Gastrointestinal Diseases; Humans; Malaria, Vivax; Male; Nausea; Sex Characteristics | 2007 |
Randomized dose-ranging study of the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Malaria, Vivax; Male; Prospective Studies; Recurrence; Thailand | 1999 |
Malaria prophylaxis/radical cure: recent experiences of the Australian Defence Force.
Topics: Aminoquinolines; Antimalarials; Australia; Controlled Clinical Trials as Topic; Endemic Diseases; Humans; Malaria; Malaria, Falciparum; Malaria, Vivax; Military Personnel; Primaquine | 2001 |
Population pharmacokinetics of the new antimalarial agent tafenoquine in Thai soldiers.
Topics: Administration, Oral; Adult; Aminoquinolines; Antimalarials; Artemisinins; Artesunate; Computer Simulation; Doxycycline; Half-Life; Humans; Malaria, Vivax; Male; Metabolic Clearance Rate; Middle Aged; Military Personnel; Models, Biological; Observer Variation; Sesquiterpenes; Thailand | 2001 |
28 other study(ies) available for tafenoquine and Plasmodium vivax Malaria
Article | Year |
---|---|
Tafenoquine for the prevention of Plasmodium vivax malaria relapse.
Topics: Aminoquinolines; Humans; Malaria, Vivax; Primaquine; Recurrence | 2021 |
Cost-Benefit Analysis of Tafenoquine for Radical Cure of
Topics: Aminoquinolines; Antimalarials; Cost-Benefit Analysis; Humans; Malaria, Vivax; Primaquine; Recurrence | 2022 |
Tafenoquine and artemisinin-based combination therapy for vivax malaria: end of the road or just the beginning?
Topics: Aminoquinolines; Antimalarials; Artemisinins; Humans; Malaria, Vivax; Plasmodium vivax | 2023 |
Killing of Plasmodium vivax by Primaquine and Tafenoquine.
Topics: Aminoquinolines; Antimalarials; Humans; Hydrogen Peroxide; Malaria, Vivax; Plasmodium vivax; Primaquine; Recurrence | 2019 |
Cost-utility of tafenoquine vs. primaquine for the radical cure (prevention of relapse) of
Topics: Aminoquinolines; Antimalarials; Cost-Benefit Analysis; Humans; Malaria, Vivax; Markov Chains; Monte Carlo Method; Primaquine; Recurrence; Serbia | 2020 |
Tafenoquine: A Step toward Malaria Elimination.
Topics: Aminoquinolines; Anemia, Hemolytic; Animals; Antimalarials; Cytochrome P-450 CYP2D6; Gene Knockdown Techniques; Glucosephosphate Dehydrogenase Deficiency; Haplorhini; Humans; Malaria, Vivax; Methemoglobinemia; Mice; Plasmodium cynomolgi; Plasmodium vivax; Zebrafish | 2020 |
Cost-Effectiveness Analysis of Sex-Stratified
Topics: Adult; Afghanistan; Aminoquinolines; Anemia, Hemolytic; Antimalarials; Chloroquine; Cost-Benefit Analysis; Ethiopia; Female; Glucosephosphate Dehydrogenase Deficiency; Hemizygote; Heterozygote; Homozygote; Humans; Indonesia; Malaria, Vivax; Male; Mass Screening; Medication Adherence; Plasmodium vivax; Primaquine; Quality-Adjusted Life Years; Recurrence; Sex Factors; Vietnam | 2020 |
Pharmacogenetic assessment of tafenoquine efficacy in patients with Plasmodium vivax malaria.
Topics: Adult; Aminoquinolines; Antimalarials; Chromosomes, Human, Pair 12; Clinical Trials as Topic; Female; Genome-Wide Association Study; Humans; Malaria, Vivax; Male; Middle Aged; Pharmacogenomic Testing; Polymorphism, Single Nucleotide; Retrospective Studies; Treatment Outcome; Young Adult | 2020 |
Letter to the editor: G6PD deficiency in the Tafenoquine era.
Topics: Aminoquinolines; Antimalarials; Contraindications, Drug; Female; Glucosephosphate Dehydrogenase Deficiency; Humans; Malaria, Vivax; Male; Mass Screening; Military Personnel; Plasmodium vivax; Population Surveillance; Prevalence; United States | 2020 |
Towards one standard treatment for uncomplicated Plasmodium falciparum and Plasmodium vivax malaria: Perspectives from and for the Peruvian Amazon.
Topics: Adult; Aminoquinolines; Artemisinins; Female; Humans; Malaria, Falciparum; Malaria, Vivax; Peru; Plasmodium falciparum; Plasmodium vivax; Prevalence; Primaquine; Reference Standards | 2021 |
Relapses of
Topics: Aminoquinolines; Disease Eradication; Humans; India; Malaria, Vivax; Recurrence | 2021 |
Estimated impact of tafenoquine for Plasmodium vivax control and elimination in Brazil: A modelling study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminoquinolines; Antimalarials; Brazil; Child; Child, Preschool; Disease Eradication; Female; Humans; Infant; Infant, Newborn; Malaria, Vivax; Male; Middle Aged; Models, Theoretical; Plasmodium vivax; Prevalence; Secondary Prevention; Young Adult | 2021 |
Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Female; Glucosephosphate Dehydrogenase Deficiency; Heterozygote; Humans; Lactation; Malaria, Vivax; Male; Plasmodium vivax; Pregnancy; Primaquine; Young Adult | 2018 |
Validation of the quantitative point-of-care CareStart biosensor for assessment of G6PD activity in venous blood.
Topics: Adult; Aminoquinolines; Antimalarials; Area Under Curve; Biosensing Techniques; Clinical Enzyme Tests; Endemic Diseases; Ethnicity; Female; Genotype; Glucosephosphate Dehydrogenase; Glucosephosphate Dehydrogenase Deficiency; Hemoglobinometry; Humans; Malaria, Vivax; Male; Methemoglobinemia; Myanmar; Point-of-Care Systems; Pregnancy; Pregnancy Complications, Hematologic; Primaquine; ROC Curve; Spectrophotometry, Ultraviolet | 2018 |
Tafenoquine receives regulatory approval in USA for prophylaxis of malaria and radical cure of Plasmodium vivax.
Topics: Aminoquinolines; Antimalarials; Drug Approval; Humans; Malaria, Vivax; Plasmodium vivax; Secondary Prevention; United States; United States Food and Drug Administration | 2018 |
Tafenoquine for travelers' malaria: evidence, rationale and recommendations.
Topics: Adult; Aminoquinolines; Antimalarials; Dose-Response Relationship, Drug; Female; Humans; Infection Control; Malaria; Malaria, Vivax; Male; Travel; United States; United States Food and Drug Administration | 2018 |
Tafenoquine - A Radical Improvement?
Topics: Aminoquinolines; Humans; Malaria, Vivax; Primaquine; Recurrence | 2019 |
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Aminoquinolines; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine; Recurrence | 2019 |
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Aminoquinolines; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine; Recurrence | 2019 |
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria. Reply.
Topics: Aminoquinolines; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine; Recurrence | 2019 |
The
Topics: Aminoquinolines; Animals; Antimalarials; Biomarkers; Biomarkers, Pharmacological; Hepatocytes; Host-Parasite Interactions; Humans; Liver; Macaca mulatta; Malaria, Vivax; Plasmodium cynomolgi; Plasmodium vivax; Protozoan Proteins; Sporozoites; Transcriptome | 2019 |
Single-dose radical cure of Plasmodium vivax: a step closer.
Topics: Aminoquinolines; Antimalarials; Chloroquine; Female; Humans; Malaria, Vivax; Male | 2014 |
A retrospective analysis of the protective efficacy of tafenoquine and mefloquine as prophylactic anti-malarials in non-immune individuals during deployment to a malaria-endemic area.
Topics: Aminoquinolines; Antimalarials; Australia; Chemoprevention; Endemic Diseases; Humans; Incidence; Malaria, Falciparum; Malaria, Vivax; Mefloquine; Military Personnel; Retrospective Studies; Timor-Leste; Travel; Treatment Outcome; United States | 2014 |
The chemotherapy of rodent malaria. LXI. Drug combinations to impede the selection of drug resistance, part 4: the potential role of 8-aminoquinolines.
Topics: Aminoquinolines; Animals; Antimalarials; Chloroquine; Disease Models, Animal; Drug Resistance; Drug Therapy, Combination; Malaria; Malaria, Falciparum; Malaria, Vivax; Mefloquine; Mice; Plasmodium berghei; Plasmodium chabaudi; Plasmodium yoelii; Primaquine; Time Factors | 2003 |
Transmission-blocking activity of tafenoquine (WR-238605) and artelinic acid against naturally circulating strains of Plasmodium vivax in Thailand.
Topics: Aminoquinolines; Animals; Anopheles; Antimalarials; Artemisinins; Dose-Response Relationship, Drug; Humans; Insect Vectors; Malaria, Vivax; Mice; Parasitic Sensitivity Tests; Plasmodium vivax; Primaquine; Sesquiterpenes | 2003 |
Treatment of acute vivax malaria with tafenoquine.
Topics: Acute Disease; Administration, Oral; Adult; Aminoquinolines; Antimalarials; Humans; Malaria, Vivax; Male; Parasitemia; Treatment Outcome | 2005 |
Tafenoquine for the treatment of recurrent Plasmodium vivax malaria.
Topics: Adult; Aminoquinolines; Antimalarials; Chloroquine; Humans; Malaria, Vivax; Recurrence | 2007 |
WR 238605, chloroquine, and their combinations as blood schizonticides against a chloroquine-resistant strain of Plasmodium vivax in Aotus monkeys.
Topics: Aminoquinolines; Animals; Antimalarials; Aotus trivirgatus; Chloroquine; Drug Resistance; Drug Therapy, Combination; Malaria, Vivax; Parasitemia | 1997 |